Petros Ioannou1, Alexandra Vouidaski2, Nikolaos Spernovasilis3, Christina Alexopoulou4, Andria Papazachariou2, Eleni Paraschou2, Aikaterini Achyropoulou2, Sofia Maraki5, George Samonis6, Diamantis P Kofteridis6. 1. MD, MSc, PhD Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Stavrakia and Voutes crossroad, Heraklion, PC 71110, Crete, Greece. 2. MD, Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, PC 71110, Crete, Greece. 3. MD, MSc Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, PC 71110, Crete, Greece. 4. MD, PhD, Intensive Care Unit, University Hospital of Heraklion, Heraklion, PC 71110, Crete, Greece. 5. MD, PhD, Department of Microbiology, University Hospital of Heraklion, Heraklion, PC 71110 Crete, Greece. 6. MD, PhD, Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, PC 71110, Crete, Greece.
Abstract
INTRODUCTION: Isolation of Candida spp. from bronchial samples of patients on mechanical ventilation is common. Even though it may not always reflect infection, it may induce immunological changes that can facilitate bacterial pneumonia. In this case, antifungal treatment is of uncertain value. This study examined the impact of antifungal treatment on the outcome of intensive care unit (ICU)-acquired respiratory tract infection (RTI) of critically ill, immunocompetent patients, with Candida isolation from their respiratory tract. METHODS: This is a retrospective cohort study of adult patients hospitalized in the ICU of the University Hospital of Heraklion, Greece, from 2014 through 2016 with ICU-acquired RTI and Candida spp. isolated from their bronchial secretions. Data regarding medical history, demographics (gender, age), reason for ICU admission, previous antimicrobial use or hospitalization, SOFA and APACHE II score, clinical outcomes (primary clinical outcome: overall mortality during hospitalization; secondary clinical outcome: mortality during the ICU stay and duration of ICU and hospital stay) at the end of their ICU stay and at the end of their hospital stay were recorded and consequently evaluated. A logistic regression analysis model evaluated the effect of the recorded parameters in association with ICU mortality and overall mortality during hospitalization. RESULTS: A total of 90 individuals were enrolled. Of them, 47 (52.2%) were treated with antifungals during their hospitalization around the time of Candida isolation. Patients treated with antifungals had higher SOFA and APACHE II scores, longer duration of stay in the ICU, more days on ventilator and higher total mortality during hospitalization. Multivariate logistic regression analysis identified antifungal use to be independently associated with total mortality during hospitalization. CONCLUSIONS: Antifungal use in patients with ICU-acquired RTI was associated with higher overall mortality as compared to those not receiving such agents. GERMS.
INTRODUCTION: Isolation of Candida spp. from bronchial samples of patients on mechanical ventilation is common. Even though it may not always reflect infection, it may induce immunological changes that can facilitate bacterial pneumonia. In this case, antifungal treatment is of uncertain value. This study examined the impact of antifungal treatment on the outcome of intensive care unit (ICU)-acquired respiratory tract infection (RTI) of critically ill, immunocompetent patients, with Candida isolation from their respiratory tract. METHODS: This is a retrospective cohort study of adult patients hospitalized in the ICU of the University Hospital of Heraklion, Greece, from 2014 through 2016 with ICU-acquired RTI and Candida spp. isolated from their bronchial secretions. Data regarding medical history, demographics (gender, age), reason for ICU admission, previous antimicrobial use or hospitalization, SOFA and APACHE II score, clinical outcomes (primary clinical outcome: overall mortality during hospitalization; secondary clinical outcome: mortality during the ICU stay and duration of ICU and hospital stay) at the end of their ICU stay and at the end of their hospital stay were recorded and consequently evaluated. A logistic regression analysis model evaluated the effect of the recorded parameters in association with ICU mortality and overall mortality during hospitalization. RESULTS: A total of 90 individuals were enrolled. Of them, 47 (52.2%) were treated with antifungals during their hospitalization around the time of Candida isolation. Patients treated with antifungals had higher SOFA and APACHE II scores, longer duration of stay in the ICU, more days on ventilator and higher total mortality during hospitalization. Multivariate logistic regression analysis identified antifungal use to be independently associated with total mortality during hospitalization. CONCLUSIONS: Antifungal use in patients with ICU-acquired RTI was associated with higher overall mortality as compared to those not receiving such agents. GERMS.
Entities:
Keywords:
Candida; ICU; VAP; antifungal; colonization; critical care
Authors: David R Williamson; Martin Albert; Marc M Perreault; Marie-Soleil Delisle; John Muscedere; Coleman Rotstein; Xuran Jiang; Daren K Heyland Journal: Can J Anaesth Date: 2010-12-14 Impact factor: 5.063
Authors: Martin Albert; David Williamson; John Muscedere; Francois Lauzier; Coleman Rotstein; Salmaan Kanji; Xuran Jiang; Mark Hall; Daren Heyland Journal: Intensive Care Med Date: 2014-07-01 Impact factor: 17.440
Authors: David S Y Ong; Peter M C Klein Klouwenberg; Cristian Spitoni; Marc J M Bonten; Olaf L Cremer Journal: Crit Care Date: 2013-10-11 Impact factor: 9.097
Authors: Ferdinand Sedlmayer; Dennis Hell; Marius Müller; David Ausländer; Martin Fussenegger Journal: Nat Commun Date: 2018-05-08 Impact factor: 14.919